Saturday

104th Scientific Assembly and Annual Meeting
November 25–30 | McCormick Place, Chicago
Participants
Thaddeus A. Wilson, PhD, Madison, WI (Moderator) Nothing to Disclose

Sub-Events

**SPPH01A PET/CT Introduction and Clinical Applications**

Participants
Osama R. Mawlawi, PhD, Houston, TX (Presenter) Research Grant, General Electric Company; Research Grant, Siemens AG

For information about this presentation, contact:
omawlawi@mdanderson.org

LEARNING OBJECTIVES
1) Describe the latest advances in hardware and software for PET/CT imaging. 2) Explain how these advances affect PET image quality and quantification. 3) Describe novel PET/CT clinical applications using new radiopharmaceuticals. 4) Discuss future developments and clinical applications of PET/CT imaging.

**SPPH01B PET/MR Introduction and Clinical Applications**

Participants
Robert A. Pooley, PhD, Jacksonville, FL (Presenter) Nothing to Disclose

For information about this presentation, contact:
pooley.robert@mayo.edu

LEARNING OBJECTIVES
1) Describe reasons for combining PET and MR into a single scanner. 2) Explain how PET instrumentation can affect MR, and how MR instrumentation can affect PET. 3) Identify PETMR protocol acquisition strategies. 4) Describe clinical applications of PETMR.

**SPPH01C Quantitative SPECT**

Participants
Benjamin M. Tsui, PhD, Baltimore, MD (Presenter) Researcher, Koninklijke Philips NV; License agreement, General Electric Company;

For information about this presentation, contact:
btsui1@jhmi.edu

LEARNING OBJECTIVES
1) Define quantitation and quantitative SPECT. 2) List and describe the image degrading factors of SPECT. 3) Describe methods to compensate for the SPECT image degrading factors. 4) Assess quality and quantitative accuracy improvements of quantitative SPECT images. 5) Apply quantitative SPECT to clinical practices.

ABSTRACT
Recent development and application of quantitative SPECT have provided significantly improved image quality and quantitative accuracy that aid in clinical diagnosis and treatment of diseases. In this educational course, we will define quantitation, quantitative SPECT and its goals. The image degrading factors of SPECT will be listed and described. Methods that compensates for the image degradation factors will be presented and explained. Examples of improvements in image quality and quantitative accuracy in various clinical applications will be presented.

Active Handout: Benjamin M. Tsui

**NIH Grantsmanship Workshop**

**Saturday, Nov. 24 1:00PM - 5:00PM Room: E253AB**

AMA PRA Category 1 Credits™: 4.00
ARRT Category A+ Credit: 0

**Participants**
Gayle E. Woloschak, PhD, Chicago, IL (Moderator) Nothing to Disclose

**LEARNING OBJECTIVES**
1) Gain greater understanding of the NIH grants process: a. Understand the process for preparing a research or training grant application. b. Learn the elements of a competitive grant application. 2) Gain insight into the new features of the NIH review process. 3) View the review process in action through a mock study section.

**Sub-Events**

**SPGW01A  Welcome and Introductory Remarks**

Participants
Gayle E. Woloschak, PhD, Chicago, IL (Presenter) Nothing to Disclose

**LEARNING OBJECTIVES**
View Learning Objectives under main course title.

**SPGW01B  Preparing an R01 Research Application**

Participants
Maryellen L. Giger, PhD, Chicago, IL (Presenter) Stockholder, Hologic, Inc; Shareholder, Quantitative Insights, Inc; Shareholder, QView Medical, Inc; Co-founder, Quantitative Insights, Inc; Royalties, Hologic, Inc; Royalties, General Electric Company; Royalties, MEDIAN Technologies; Royalties, Riverain Technologies, LLC; Royalties, Mitsubishi Corporation; Royalties, Canon Medical Systems Corporation

For information about this presentation, contact:
m-giger@uchicago.edu

**LEARNING OBJECTIVES**
View Learning Objectives under main course title.

**SPGW01C  Preparing K Awards**

Participants
Ruth C. Carlos, MD, MS, Ann Arbor, MI (Presenter) Nothing to Disclose

**LEARNING OBJECTIVES**
View Learning Objectives under main course title.

**Honored Educators**

Presenters or authors on this event have been recognized as RSNA Honored Educators for participating in multiple qualifying educational activities. Honored Educators are invested in furthering the profession of radiology by delivering high-quality educational content in their field of study. Learn how you can become an honored educator by visiting the website at: https://www.rsna.org/Honored-Educator-Award/

Ruth C. Carlos, MD, MS - 2015 Honored Educator
Ruth C. Carlos, MD, MS - 2018 Honored Educator

**SPGW01D  Clinical Trials in Applications**

Participants
Michael W. Vannier, MD, Crete, IL (Presenter) Nothing to Disclose

**LEARNING OBJECTIVES**
View Learning Objectives under main course title.

**Honored Educators**

Presenters or authors on this event have been recognized as RSNA Honored Educators for participating in multiple qualifying educational activities. Honored Educators are invested in furthering the profession of radiology by delivering high-quality educational content in their field of study. Learn how you can become an honored educator by visiting the website at: https://www.rsna.org/Honored-Educator-Award/

Michael W. Vannier, MD - 2015 Honored Educator
Program Perspectives

Participants
Manana Sukhareva, PhD, Bethesda, MD (Presenter) Nothing to Disclose

LEARNING OBJECTIVES
View Learning Objectives under main course title.

ABSTRACT

The Process of Review

Participants
Gayle E. Woloschak, PhD, Chicago, IL (Presenter) Nothing to Disclose

LEARNING OBJECTIVES
View Learning Objectives under main course title.

Mock Study Section

Participants
Gayle E. Woloschak, PhD, Chicago, IL (Presenter) Nothing to Disclose
Maryellen L. Giger, PhD, Chicago, IL (Presenter) Stockholder, Hologic, Inc; Shareholder, Quantitative Insights, Inc; Shareholder, QView Medical, Inc; Co-founder, Quantitative Insights, Inc; Royalties, Hologic, Inc; Royalties, General Electric Company; Royalties, MEDIAN Technologies; Royalties, Riverain Technologies, LLC; Royalties, Mitsubishi Corporation; Royalties, Canon Medical Systems Corporation
Ruth C. Carlos, MD, MS, Ann Arbor, MI (Presenter) Nothing to Disclose
Michael W. Vannier, MD, Crete, IL (Presenter) Nothing to Disclose
Elizabeth A. Krupinski, PhD, Atlanta, GA (Presenter) Nothing to Disclose

For information about this presentation, contact:
ekrupin@emory.edu
m-giger@uchicago.edu

LEARNING OBJECTIVES
1) Understand how an NIH review session takes place.

Honored Educators

Presenters or authors on this event have been recognized as RSNA Honored Educators for participating in multiple qualifying educational activities. Honored Educators are invested in furthering the profession of radiology by delivering high-quality educational content in their field of study. Learn how you can become an honored educator by visiting the website at: https://www.rsna.org/Honored-Educator-Award/ Ruth C. Carlos, MD, MS - 2015 Honored EducatorRuth C. Carlos, MD, MS - 2018 Honored EducatorMichael W. Vannier, MD - 2015 Honored EducatorElizabeth A. Krupinski, PhD - 2017 Honored Educator

Questions to the Faculty

Participants
Gayle E. Woloschak, PhD, Chicago, IL (Presenter) Nothing to Disclose

LEARNING OBJECTIVES
View Learning Objectives under main course title.

Summary

Participants
Gayle E. Woloschak, PhD, Chicago, IL (Presenter) Nothing to Disclose

LEARNING OBJECTIVES
View Learning Objectives under main course title.

Adjourn
**SPPH02**

**AAPM/RSNA Physics Tutorial Session 2**

Saturday, Nov. 24 2:15PM - 4:15PM Room: E351

**LEARNING OBJECTIVES**

1) Understand current models and methods used in radiation dosimetry for radiopharmaceuticals. 2) Understand methods for new drug approval with the FDA. 3) Understand current experience with radiopharmaceuticals used in therapy: types of compounds, clinical experience, biological effects.

**ABSTRACT**

Advances in the understanding of cancer biology, developments in diagnostic technologies, and expansion of therapeutic options have all contributed to the concept of personalized cancer care. Theranostics is the systematic integration of targeted diagnostics and therapeutics. The theranostic platform includes an imaging component that ‘sees’ the lesions followed by administration of the companion therapy agent that ‘treats’ the same lesions. This strategy leads to enhanced therapy efficacy, manageable adverse events, improved patient outcome, and lower overall costs. In this lecture, I review the the concept, history, recent developments, current challenges, and outlook for radiotheranostics (use of radionuclides in theranostics) in the management of patients with cancer (Jadvar H et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018; 286:388-400).

---

**Participants**

Thaddeus A. Wilson, PhD, Madison, WI (Moderator) Nothing to Disclose

**Sub-Events**

**SPPH02A The Nuts and Bolts of Dosimetry in Nuclear Medicine and its Application**

Participants

Michael G. Stabin, PhD, Nashville, TN (Presenter) Software, Vanderbilt University

**LEARNING OBJECTIVES**

1) Define theranostic. 2) Review the history and current clinical applications of theranostics. 3) Describe potential outlook for theranostics in the era of precision medicine.

**SPPH02B Theranostics Introduction and Applications**

Participants

Hossein Jadvar, MD, PhD, Pasadena, CA (Presenter) Nothing to Disclose

For information about this presentation, contact:

jadvar@med.usc.edu

**LEARNING OBJECTIVES**

1) Define theranostic. 2) Review the history and current clinical applications of theranostics. 3) Describe potential outlook for theranostics in the era of precision medicine.